United States: The 21st Century Cures Act

On December 13, 2016, President Obama signed the 21st Century Cures Act into law.

The Cures Act, which sailed through both the House of Representatives (392-26) and the Senate (94-5), is a massive piece of bipartisan legislation focused on advancing and accelerating medical research. Additionally, the Cures Act contains provisions devoted to fighting America's opioid abuse epidemic and improving mental health care.

Described by the House Committee on Energy and Commerce as "[a]n innovation game-changer, a once-in-a-generation, transformational opportunity to change the way we treat disease,"1 the Cures Act is the result of "conversations with patients, researchers, innovators, and health care professionals about what steps can be taken to expedite the discovery, development and delivery of new treatment and cures and maintain America's global status as the leader in biomedical innovation."2

Given its sweeping scope, the White House believes that the Cures Act "will go a long way toward bringing about the medical breakthroughs we need to meet some of the biggest health challenges facing Americans today."3 Based on the overwhelming support of Congress, the pharmaceutical and medical device industries, PhARMA, patient advocacy groups such as FasterCures, and numerous medical societies and foundations4, it is clear that many share this view.

However, critics of the Cures Act, including Senators Bernie Sanders and Elizabeth Warren as well as consumer watchdog groups like Public Citizen's Health Research Group and the National Center for Health Research, fear that the advancements envisioned by the Act undermine the Food and Drug Administration's ability to protect patients and will ultimately endanger public health and safety.5 While by no means an exhaustive list, key provisions of the 21st Century Cures Act include:6

  • Allocation of $4.8 billion over 10 years to the National Institute of Health for innovative research programs including the following:
    • Cancer Moonshot Initiative (acceleration of cancer research and availability of treatment options)
    • Precision Medicine Initiative (research of disease prevention, diagnosis, and treatment methods tailored to people's unique characteristics)
    • Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (research of brain disorders, such as Alzheimer's and Parkinson's diseases, depression, and traumatic brain injury)
    • Regenerative medicine using adult stem cells (includes cell therapy, gene therapy, therapeutic tissue engineering products, human cell and tissue products)
  • Allocation of $1 billion over 2 years for grants to states for opioid abuse prevention and treatment.
  • Implementation of provisions to move drugs and devices to patients more quickly
    • Establishes a review pathway at the FDA for biomarkers and other drug development tools used to help shorten drug development time and reduce the failure rate in drug development
    • Requires the FDA to evaluate the usefulness of data collected outside of randomized clinical trials (i.e. information that is currently considered off-label) and establishes a regulatory framework that would be used to determine the usefulness of real-world data
    • Allows drug manufacturers to share off-label uses with insurance companies
    • Allows sponsors of genetically targeted or variant protein targeted drugs to rely on data for the same or similar technology from its previously approved applications
    • Requires HHS to harmonize differences between the Common Rule and the Food, Drug and Cosmetics Act with respect to protection of human subjects
    • Allows the FDA to rely on qualified data summaries to support approval of application for new indication of an approved drug
    • Requires pharmaceutical companies to establish publically accessible compassionate use policies for drugs treating serious or life threatening conditions
    • Allows the FDA to grant accelerated approval for regenerative therapeutic products
    • Establishes that devices used with a regenerative therapeutic product be considered a moderate risk unless the Secretary determines otherwise
    • Improves regulation of combination products (e.g. a product that contains a drug and a device)
    • Gives the FDA the flexibility to approve antimicrobial drugs based on a limited population if the drug treats a lifethreatening condition
    • Establishes a breakthrough device approval pathway which builds on the existing priority device pathway
    • Increases the humanitarian device exemption to devices that treat diseases and conditions affecting up to 8000 individuals
    • Strikes the requirement that a sponsor of a medical device trial always use a local institutional review board
    • Requires FDA to clarify regulatory guidance to clarify the criteria for waiving CLIA requirements
    • Clarifies that FDA reviewers shall consider the least burdensome means necessary for demonstrating a reasonable assurance of safety and effectiveness when requesting additional information from manufacturers during pre-market approval
    • Encourages innovation in Medical Countermeasures and Vaccines
  • Implementation of provision designed to improve quality of patient care
    • Reduces documentation burdens on providers while maintaining quality
    • Supports a model framework for electronic health records to foster exchange of health information between networks
    • Establishes authority for the OIG to investigate claims of and assign penalties for health information blocking
  • Expansion of OIG's authority to use civil monetary penalties in cases of proven HHS grant or contract fraud
  • Increased oversight by states for termination of Medicaid/ CHIP providers
  • Extension/Implementation of provisions relating to Medicare including provisions related to Rural Community Hospitals, Long-Term Care Hospitals, Hospital Outpatient Departments, and Ambulatory Surgery Centers
  • Implementation of reforms for mental healthcare including:
    • Mental health parity enforcement
    • Early intervention programs
    • Suicide prevention programs

Be on the lookout in future editions of Pro Te Solutio for more in-depth analysis of the Cures Act and its potential impact on the healthcare industry.


1 https://energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/documents/114/analysis/20161128%20Cures%20Fact%20Sheet.pdf

2 Id.

3 https://wwzw.whitehouse.gov/blog/2016/12/12/3-letters-explain-whypresident-obama-signing-cures-act

4 https://energycommerce.house.gov/news-center/letters/letters-support-hr-6-21st-century-cures-act

5 https://www.washingtonpost.com/news/powerpost/wp/2016/12/07/congress-passes-21st-century-cures-act-boosting-research-and-easing-drugapprovals/?utm_term=.503cb4e712cc

6 https://rules.house.gov/sites/republicans.rules.house.gov/files/114/PDF/114-SAHR34-Sxs.pdf  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.